Evotec SE, DE0005664809

Evotec stock heads into the open after a 1.9 percent drop

Published on 09/09/2026 at 07:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 8, 2026, Evotec stock finished near EUR 3.15 on Xetra, slipping about 1.9 percent and hovering just above its 52-week low, while trading volume topped roughly 570,000 shares as investors processed weak second-quarter figures. Today, broader market cues remain in focus.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage
Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock closed at about EUR 3.15 on Xetra on September 8, 2026, down roughly 1.9 percent from the previous session as the shares stayed close to their recent 52-week low.

September 8, 2026 in numbers

Evotec SE (ISIN DE0005664809) ended the Xetra session on September 8, 2026 at approximately EUR 3.15, losing about 1.9 percent versus the prior close, with intraday prices reported between an estimated low near EUR 3.13 and levels just above EUR 3.19 and trading volume indicated at more than 570,000 shares for the day, per German market data. According to an intraday wrap from Ad-hoc-news.de, the stock traded just above its 52-week low around EUR 3.12 on September 8, 2026, underlining the ongoing pressure on the share price. The same report noted that Evotec's second-quarter 2026 results showed a loss of EUR 0.26 per share for the quarter ended June 30, 2026, compared with a loss of EUR 0.24 per share a year earlier, a widening of about 8.3 percent in quarterly loss per share that has weighed on sentiment.

Market data cited by Ad-hoc-news.de also highlight that analysts currently expect Evotec to post a full-year 2026 loss of around EUR 1.297 per share, reinforcing the perception that the company will remain loss-making this year. In the same session, the broader European equity benchmarks were described as mixed, with large-cap indices moving only modestly, suggesting that Evotec's decline on September 8, 2026 was driven more by company-specific concerns around its earnings trajectory than by a sharp market-wide selloff.

Today’s outlook for Evotec

Company calendars in recent days show no scheduled earnings release or major corporate event for Evotec on September 9, 2026, and the next earnings date referenced for Evotec's Nasdaq-listed shares is estimated for November 5, 2026 according to MarketBeat. As a result, trading into today's session is likely to remain shaped by the recently reported second-quarter loss and by broader moves in European and global equity benchmarks, with investors watching whether the share price can stabilize above the cited 52-week low zone around EUR 3.12 while digesting expectations for a continued full-year loss in 2026.

Disclaimer...

en | DE0005664809 | EVOTEC SE | boerse | 70073045 | bgmi